INDV Q2 2023 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$276M+24.9% YoY

Gross Profit

$226M81.9% margin

Operating Income

$61M22.1% margin

Net Income

$39M14.1% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

+9.1%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$1.6B

Stockholders' Equity

$117M

Cash & Equivalents

$592M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$276M	$221M	+24.9%
Gross Profit	$226M	$183M	+23.5%
Operating Income	$61M	$63M	-3.2%
Net Income	$39M	$48M	-18.8%